Microplastics have emerged as one of the most widely discussed environmental contaminants of our time. Regardless of where we live, daily exposure to microplastics has become virtually unavoidable—these tiny plastic particles are present in the air we breathe, the water we drink, and the environments we inhabit. As researchers work to better understand the sources, transport pathways, and impacts of microplastics, the demand for reliable microplastic analysis methods continues to grow.While techniques such as FTIR and Raman spectroscopy have become standard tools for identifying microplastics, their utility is limited for smaller particles (i.e. nanoplastics) and in complex matrices. More advanced microplastic analysis methods can provide a deeper understanding of what these particles contain and how they may change over time in the environment.<div><h3>The Limits of Spectroscopic Microplastic Analysis Methods</h3>Fourier-Transform Infrared (FTIR) and Raman spectroscopy are widely used microplastic analysis methods because they can identify polymer types by measuring how electromagnetic radiation interacts with a material. These techniques are valuable for determining whether a particle is polyethylene, polypropylene, polystyrene, or another common plastic. For many studies, this information is sufficient to confirm the presence of microplastics, especially in clean samples with sufficient microplastic density.However, <a target="_blank" rel="noopener noreferrer" href="https://www.leco.com/application/environmental/">environmental samples</a> are rarely clean and compositionally simple. Microplastic particles can become weathered and obscured by other materials in the environment, making their accurate identification with spectroscopy difficult. Additionally, if researchers want to understand what additives, degradation products, or pollutants are associated with the plastic, particle identification alone is not enough. Thus, FTIR and Raman spectroscopy methods alone struggle to thoroughly characterize these complex chemical components, particularly in challenging environmental matrices. As questions surrounding microplastic exposure become increasingly important, researchers require analytical techniques capable of examining the chemistry of a sample in greater detail, not simply confirming the presence of the physical particle itself.</div><div><h3>Thermal Desorption and Pyrolysis GCxGC-TOFMS For Deeper Microplastic Analysis</h3>Thermal Desorption (TD) and Pyrolysis (Py) coupled with comprehensive two-dimensional gas chromatography and time-of-flight mass spectrometry (<a target="_blank" rel="noopener noreferrer" href="https://www.leco.com/core-analysis/gc-and-gc-ms/">GCxGC-TOFMS</a>) offer a powerful alternative for investigating nano- and microplastics in complex samples. These techniques provide complementary information about sample composition.&nbsp;Thermal desorption releases volatile and adsorbed compounds, including environmental contaminants, degradation products, and VOCs associated with microplastic particles. This can reveal important information about chemicals present within or on the plastic.Pyrolysis thermally deconstructs the polymeric material, breaking it into GC-amenable characteristic degradation compounds. These compounds act as chemical markers that can be used to identify the various polymers present. When analyzing complex or heavily weathered microplastics that may be difficult to characterize using traditional spectroscopic techniques, pyrolysis is particularly advantageous.The most significant benefit comes from pairing these techniques with comprehensive two-dimensional gas chromatography. Environmental samples often contain hundreds or even thousands of compounds that coelute in 1D GC-MS, making it difficult or impossible to identify each compound. GCxGC provides significantly greater separation capability, helping analysts distinguish important polymer markers from background matrix components. This enhanced separation improves the mass spectrometer’s ability to identify characteristic polymer pyrolysis products, even in highly complex environmental samples. As a result, researchers can detect and identify challenging microplastics without the extensive purification steps often required by other analytical workflows.Another unique advantage of this approach is that thermal desorption and pyrolysis can be used in series on the same sample. Together, they create a more complete chemical profile of the sample.</div><div><h3>A Powerful Microplastics Analysis Workflow for Deeper Insight into the Effects on Our Environment</h3>FTIR and Raman spectroscopy remain valuable tools for rapid screening and flagging samples containing microplastic particles. However, by combining thermal desorption, pyrolysis, and GCxGC-TOFMS, analysts can obtain a much more comprehensive view of plastics in their samples and their environmental implications. As environmental research continues to advance and concerns surrounding microplastic contamination grow, researchers will increasingly require information that extends beyond answering the question,&nbsp;“What plastic is present?”&nbsp;&nbsp;Ultimately, this deeper level of characterization can provide new insights into the environmental fate of microplastics and help scientists better understand their potential impacts on ecosystems and human exposure.</div>

Surpassing the Limits of Traditional Microplastic Analysis Methods with Thermal Desorption and Pyrolysis GCxGC-TOFMS

Oligonucleotide and mRNA Analysis Resource Roundup

NIST26 introduces integrated chromatogram processing, deconvolution, and library searching for EI GC-MS and LC-MS/MS data, but the workflow begins with one essential requirement: chromatographic data must be available in the mzML format. In his presentation <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/Conversion_to_mz_ML_63e134bb34.pdf">Conversion to mzML Format for NIST26 Chromatogram Processing</a>, James Little of Mass Spec Interpretation Services explains how vendor data can be converted to mzML using either instrument-vendor software or the freely available MSConvert tool from ProteoWizard, and highlights several settings that are critical for successful processing in NIST26.<h4>NIST26 Chromatogram processing requires mzML</h4>For the chromatogram-processing workflow described in the presentation, mzML is the accepted input format. Proprietary LC-MS or GC-MS data therefore need to be converted before they can be loaded into the NIST26 chromatogram-processing environment.There are two principal ways to obtain an mzML file:<ul><li>conversion using software supplied by the instrument manufacturer,</li><li>conversion using MSConvert, which is included in the free ProteoWizard software package.</li></ul>Using an open format such as mzML also provides a practical way to move mass spectrometry data between different software environments without relying exclusively on proprietary vendor formats.<h4>Using ProteoWizard and MSConvert</h4>MSConvert is installed as part of the complete ProteoWizard package rather than as a separate application. After installing ProteoWizard, users can access either the graphical MSConvert interface or the command-line version.The presentation recommends the stable release for routine work, while noting that newer or nightly builds may sometimes provide improved support for recently introduced vendor formats or additional control over data-processing filters. This can be particularly relevant when handling vendor files in which centroiding behavior or peak picking requires closer attention.For most users, the graphical interface provides a straightforward route from proprietary raw data to an mzML file suitable for further NIST26 processing.<h4>Start by selecting mzML as the output format</h4>The first step in MSConvert is to select the source file or dataset using the Browse function.The software supports a broad range of mass spectrometry data formats, and the file-selection window can either be restricted to a particular vendor format or set to display any supported spectral format.After selecting the source data, the output format must be set to mzML. The screenshots in the presentation show this setting directly in the MSConvert options panel before the conversion is started.The user can also select the destination folder and other file-output options before adding the selected dataset to the conversion queue.<h4>Add the data and start the conversion</h4>Once the source file and output settings have been selected, the file is added to the conversion list using the Add command.The conversion itself is then launched with Start.For simple datasets that are already stored in the correct spectral representation, this may be all that is required. However, James Little emphasizes an additional requirement that is particularly important for NIST26: the data must be centroided.<h4>Centroided data are required</h4>According to the presentation, profile-mode data are not acceptable for this NIST26 chromatogram-processing workflow. The spectra must instead be in centroided, or peak-picked, form.Profile spectra contain the full measured shape of each mass spectral signal across the m/z axis. Centroided data reduce these profiles to discrete peaks represented by their characteristic m/z and intensity values.If the original vendor data are still in profile mode, centroiding can be performed during conversion by adding the Peak Picking filter in MSConvert.This means that the conversion step can perform two operations at once:vendor raw data → centroiding / peak picking → mzMLThe resulting mzML file can then be used as input for NIST26 chromatogram processing.<h4>Peak Picking must be the first filter</h4>One of the most important practical details in the presentation is the position of the Peak Picking operation in the MSConvert filter sequence.If centroiding is required, Peak Picking must be the first algorithm or filter in the list. Placing another processing function before it can interfere with the intended conversion workflow.MSConvert allows the user to select the Peak Picking filter, define the relevant MS levels, and add it to the processing sequence before starting conversion. The example shown in the presentation applies vendor-based peak picking to selected MS levels.If there is uncertainty about whether the source data are already centroided, the Peak Picking filter can still be included. According to the presentation, applying it to data that are already centroided does not alter the file unnecessarily.This provides a useful safeguard when the acquisition mode of an older dataset is uncertain.<h4>Selecting the appropriate MS levels</h4>Peak picking does not necessarily have to be applied identically to every spectrum in a dataset. MSConvert allows users to specify the MS levels to which the filter should be applied.This is especially relevant for LC-MS/MS data, where a file can contain both precursor-level MS spectra and tandem MS spectra.The conversion settings should therefore reflect the way the original data were acquired and how those data will subsequently be processed in NIST26.<h4>Be aware of changes in file size</h4>The presentation also notes that converted files may become substantially different in size from the original vendor files.This is worth considering when working with large LC-MS/MS datasets or processing batches of chromatograms. The size of the resulting mzML file can depend on the original acquisition mode, centroiding, compression settings, the number of MS levels, and other output parameters.Storage requirements should therefore be considered before converting large collections of raw data.<h4>A simple workflow for preparing data for NIST26</h4>The overall procedure presented by James Little can be summarized as a short sequence:<ol><li>Obtain the original vendor LC-MS or GC-MS data.</li><li>Open the data in MSConvert or use the vendor's own conversion software.</li><li>Select mzML as the output format.</li><li>Check whether the spectra are centroided.</li><li>If necessary, add Peak Picking as the first processing filter.</li><li>Select the appropriate MS levels.</li><li>Add the file to the conversion list.</li><li>Start the conversion.</li><li>Use the resulting mzML file for NIST26 chromatogram processing.</li></ol>The procedure itself is straightforward, but the centroiding requirement is important. A file can have the correct <code>.mzML</code> extension and still be unsuitable for the workflow if its spectra remain in profile mode.<h4>From vendor data to integrated NIST26 processing</h4>File conversion may appear to be a relatively minor step compared with deconvolution, spectral interpretation, and library searching, but it establishes the foundation for the entire downstream workflow.By using mzML as the common input format, NIST26 can process data originating from different instrument platforms through a more consistent workflow. ProteoWizard and MSConvert provide a practical bridge between proprietary mass spectrometry files and this standardized format.The key message from the presentation is therefore simple: convert to mzML, ensure the spectra are centroided, and place Peak Picking first whenever centroiding is required. Once those conditions are met, the data are ready for the integrated chromatogram-processing and library-searching capabilities available in NIST26.

Conversion to mzML Format for NIST26 Chromatogram Processing

Article

Academy

Environment

Science and research

Software

Video

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

In 1936, the Laboratory Equipment Company introduced the first rapid carbon determinator for the American iron and steel industry.  Today, almost 80 years later, LECO is recognized globally as a leader in the development of high-quality analytical instrumentation, mass spectrometers, comprehensive two-dimensional chromatography, metallography & optical equipment as well as consumables.

LECO

My main interest is the identification of organic compounds by mass spectrometry in organic mixtures.

James Little/Mass Spec Interpretation Services

Sildenafil/Tadafil blend analysis

Targeted HPLC analysis of sildenafil and tadalafil blends in pills, tablets, and capsules, confirming identity and determining the amount of both compounds.

The Sildenafil/Tadalafil Blend Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sildenafil and tadalafil in combined oral dosage forms.The analysis is suitable for pills, tablets, and capsules containing both compounds, with individual results reported in milligrams per tablet or capsule.<h4>About Sildenafil and Tadalafil</h4>Sildenafil and tadalafil are orally active phosphodiesterase type 5 (PDE5) inhibitors. Both compounds inhibit PDE5 and support the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Although they belong to the same pharmacological class, sildenafil and tadalafil differ in their pharmacokinetic profiles and duration of action. This analysis is specifically designed for products containing both compounds in a single formulation.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sildenafil and tadalafil</li><li>Suitable for combined pills, tablets, and capsules</li><li>Simultaneous analysis of both target compounds</li><li>Analysis by HPLC</li><li>Results reported individually for sildenafil and tadalafil</li><li>Results reported in mg per tablet or capsule</li><li>Minimum sample amount of three tablets or capsules</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: Tadalafil and Sildenafil</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: 2 mg</li><li>Result format: mg per tablet or capsule</li><li>Minimum sample amount: Three tablets or capsules</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for products containing sildenafil and tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>The minimum amount of each target compound required for evaluation is 2 mg. Samples containing lower amounts may not be reliably evaluated within the standard scope of the analysis.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.cz/products/2525">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

GCMS/LCMS screening for contamination

GCMS/LCMS screening for identification of contaminants in samples, with the analytical method selected according to sample type.

The GCMS/LCMS Screening for Contamination is a standalone laboratory service designed to identify potential contaminants in a sample using either gas chromatography–mass spectrometry (GCMS) or liquid chromatography–mass spectrometry (LCMS).The appropriate analytical method depends on the sample type. GCMS is used primarily for volatile and semi-volatile compounds, while LCMS is suitable for peptide-related contamination.<h4>About the Screening</h4><ul><li>GCMS screening uses the NIST 2014 mass spectral library to identify a broad range of potentially harmful substances in the product. Detection is limited to volatile and semi-volatile compounds and this method is not suitable for peptide samples. &nbsp;</li><li>LCMS screening is intended for peptide products and can detect contamination with other peptides or degraded peptide. Detection is limited to peptides included in the laboratory’s available reference list.</li></ul>Both methods provide identification of detected contaminants only. Quantitative determination of a detected substance can be offered separately.<h4>Key Features</h4><ul><li>Standalone contamination screening by GCMS or LCMS</li><li>Analytical method selected according to sample type</li><li>GCMS screening for volatile and semi-volatile contaminants</li><li>GCMS identification using the NIST 2014 mass spectral library</li><li>LCMS screening for peptide contamination and degraded peptide</li><li>Identification of detected contaminants</li><li>Quantitative determination available separately after identification</li><li>Suitable for tablets, capsules, liquid solutions, raw materials, and vials depending on the selected method</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Testing method: GCMS or LCMS</li><li>Amount of sample required: 1 tablet/capsule, 1 ml solution, 200 mg raw material, or 1 vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>The analytical method is selected according to the type of sample and the expected contaminants.</li><li>GCMS detection is limited to volatile and semi-volatile compounds and cannot be used for peptide samples.</li><li>LCMS detection is limited to peptides included in the laboratory’s available reference list.</li><li>Both GCMS and LCMS screening provide identification only. Quantitative determination of a detected contaminant is not included in the standard analysis and can be offered separately.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

Heavy Metals Screening (As, Cd, Pb, Hg)

Screening of arsenic, cadmium, lead, and mercury in samples using Shimadzu EDX fluorescence spectrometry.

The Heavy Metals Screening is a standalone laboratory test designed to detect the presence of selected heavy metals in a sample.The standard screening covers arsenic (As), cadmium (Cd), lead (Pb), and mercury (Hg). Other metals may be tested upon request.<h4>About the Analyzed Metals</h4>Arsenic, cadmium, lead, and mercury are toxic elements that may occur as contaminants in raw materials, finished products, supplements, pharmaceuticals, and other sample types.Their presence can be relevant for quality control and safety assessment, especially when contamination may arise from raw materials, manufacturing, handling, or storage.<h4>Key Features</h4><ul><li>Standalone screening for selected heavy metals</li><li>Target metals: arsenic (As), cadmium (Cd), lead (Pb), and mercury (Hg)</li><li>Analysis using Shimadzu EDX fluorescence spectrometry</li><li>Suitable for tablets, capsules, liquid solutions, raw materials, and vials</li><li>Other metals can be tested upon request</li><li>Minimum sample amount of 1 tablet/capsule, 1 ml solution, 200 mg raw material, or 1 vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target metals: As, Cd, Pb, Hg</li><li>Testing method: Shimadzu EDX fluorescence spectrometer</li><li>Amount of sample required: 1 tablet/capsule, 1 ml solution, 200 mg raw material, or 1 vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>The standard screening covers arsenic, cadmium, lead, and mercury only.</li><li>If screening for other metals is required, this should be requested separately before analysis.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

CHNS Mass Report (Standalone Test)

CHNS elemental analysis determines C, H, N, and S content and provides an independent assessment of net peptide content.

The CHNS Mass Report is a standalone elemental analysis designed to determine carbon (C), hydrogen (H), nitrogen (N), and sulfur (S) content in a sample. For peptide samples, CHNS analysis can be used as an independent approach to assess net peptide content.Unlike HPLC-based amount determination, CHNS analysis is based on combustion of the sample rather than dissolution. This can help avoid solubility-related limitations that may affect some chromatographic measurements.<h4>About CHNS Analysis</h4>CHNS elemental analysis determines the proportions of carbon, hydrogen, nitrogen, and sulfur present in a sample. During analysis, the sample is combusted and the resulting elemental composition is measured.For peptides with a known elemental composition, these data can be used to evaluate the actual peptide content of the sample independently of chromatographic purity measurements.<h4>Key Features</h4><ul><li>Standalone CHNS elemental analysis</li><li>Determination of carbon, hydrogen, nitrogen, and sulfur</li><li>Combustion-based analytical method</li><li>Independent assessment of net peptide content</li><li>Avoids sample-solubility limitations associated with some HPLC measurements</li><li>Suitable for tablets, capsules, liquid solutions, raw materials, and vials</li><li>Minimum sample amount of 1 tablet/capsule, 1 ml solution, 200 mg raw material, or 1 vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Testing method: CHNS elemental analysis</li><li>Amount of sample required: 1 tablet/capsule, 1 ml solution, 200 mg raw material, or 1 vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>CHNS analysis determines elemental composition and is fundamentally different from chromatographic purity analysis.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

Sterility Testing (TAMC + TYMC)

TAMC + TYMC microbial testing for aerobic microorganisms, yeasts, and molds in unopened vials, ampoules, and liquid samples.

The Sterility Testing service is designed to assess microbial contamination in suitable samples using Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) cultivation tests.The analysis is intended primarily for unopened peptide vials, ampoules, and other liquid samples where microbial contamination may affect product quality and safety.<h4>About TAMC and TYMC</h4>TAMC determines the total number of viable aerobic microorganisms present in a sample, while TYMC evaluates the presence of viable yeasts and molds.Together, these cultivation-based tests provide an assessment of the overall microbial burden of the sample. Results are reported as Pass or Fail according to the applied acceptance criteria.<h4>Key Features</h4><ul><li>Cultivation-based microbial testing</li><li>Total Aerobic Microbial Count (TAMC)</li><li>Total Yeast and Mold Count (TYMC)</li><li>Suitable for unopened peptide vials, ampoules, and selected liquid samples</li><li>Recommended sample amount of two unopened peptide vials</li><li>Alternative sample formats include two 1 ml ampoules or one 10 ml vial</li><li>Results reported as Pass or Fail</li><li>Average turnaround time of 14 days</li></ul><h4>Analysis Parameters</h4><ul><li>Testing method: Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC)</li><li>Amount required for the test: Two unopened peptide vials recommended, two 1 ml ampoules, or one 10 ml vial (e.g. oil-based samples)</li><li>Result format: Pass or Fail</li><li>Average turnaround time: 14 days</li></ul><blockquote>Important Notice<ul><li>Unopened vials or ampoules are required to minimise the risk of contamination during shipping and handling.</li><li>Submitting less than the recommended sample amount is possible, but it may affect the reliability of the results.</li><li>This test is not recommended for oral products, as oral dosage forms are not generally required to be sterile for safe use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Additional Laboratory Report</li></ul>

2,4-Dinitrophenol (DNP) Analysis

Targeted HPLC analysis of 2,4-dinitrophenol (DNP) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The 2,4-Dinitrophenol (DNP) Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of 2,4-dinitrophenol in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About 2,4-Dinitrophenol (DNP)</h4>2,4-Dinitrophenol (DNP) is a synthetic chemical compound that acts as an uncoupler of oxidative phosphorylation, disrupting normal cellular energy production and increasing heat generation.DNP has historically been investigated for several industrial and biological applications but is highly toxic and is not approved as a weight-loss drug. Exposure can cause serious and potentially life-threatening adverse effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of 2,4-dinitrophenol (DNP)</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: 2,4-Dinitrophenol</li><li>Other name: DNP</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 20 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for 2,4-dinitrophenol (DNP). It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of DNP required for evaluation is 20 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>DNP is a highly toxic compound. Laboratory analysis should not be interpreted as confirmation that a product is safe for human consumption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

5-Amino-1-methylquinolinium Analysis

Targeted HPLC analysis of 5-Amino-1-methylquinolinium in pills, tablets, capsules, and raw API powders for identity and amount determination.

The 5-Amino-1-methylquinolinium Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of 5-Amino-1-methylquinolinium in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by mass-by-mass purity in %. Please note that 5-Amino-1-methylquinolinium is not a peptide, and peptide purity is therefore not determined.<h4>About 5-Amino-1-methylquinolinium</h4>5-Amino-1-methylquinolinium, also known as 5A1MQ or 5-Amino-1MQ, is a small-molecule research compound investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide.NNMT is an enzyme involved in nicotinamide and cellular methylation metabolism. 5-Amino-1-methylquinolinium has been studied primarily in preclinical research related to cellular metabolism and adipose tissue biology.<h4>Key Features</h4><ul><li>Targeted identification and quantification of 5-Amino-1-methylquinolinium</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format reported as purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: 5-Amino-1-methylquinolinium</li><li>Other names: 5A1MQ, 5-Amino-1MQ</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>5-Amino-1-methylquinolinium is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for 5-Amino-1-methylquinolinium. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances unless an additional screening service is ordered.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>Iodide/Chloride Analysis</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

AICAR analysis

Targeted HPLC analysis of AICAR in finished lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

The AICAR Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of AICAR in finished lyophilised vials and raw active pharmaceutical ingredient (API) powders.For finished vials, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). AICAR is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About AICAR</h4>AICAR is a small-molecule research compound widely used in studies of cellular energy metabolism and AMP-activated protein kinase (AMPK) signalling. After cellular uptake, AICAR riboside can be phosphorylated to ZMP, an AMP analogue that can activate AMPK.AICAR has been investigated extensively in preclinical research examining metabolic regulation, glucose and lipid metabolism, and cellular responses to changes in energy availability. Its effects are not exclusively mediated through AMPK, and additional AMPK-independent mechanisms have also been described.<h4>Key Features</h4><ul><li>Targeted identification and quantification of AICAR</li><li>Suitable for finished lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for finished vials reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: AICAR</li><li>Testing method: HPLC</li><li>Result format for finished vial: mg per vial</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for finished vial: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>AICAR is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For finished products, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a> (TAMC and TYMC)</li><li>Additional Laboratory Report</li></ul>

BAC Water (Benzyl Alcohol) Analysis

HPLC analysis of benzyl alcohol in bacteriostatic water, including confirmation and concentration determination in mg/ml.

The BAC Water (Benzyl Alcohol) Analysis is a targeted laboratory test designed to confirm the presence and determine the concentration of benzyl alcohol in bacteriostatic water.The analysis is performed by HPLC, with results reported in milligrams of benzyl alcohol per millilitre of sample.<h4>About Benzyl Alcohol</h4>Benzyl alcohol is an aromatic alcohol commonly used as a preservative in pharmaceutical and laboratory formulations. In bacteriostatic water, it is added to help inhibit microbial growth after a vial has been opened.This analysis specifically determines the concentration of benzyl alcohol in the submitted liquid sample.<h4>Key Features</h4><ul><li>Targeted identification and quantification of benzyl alcohol</li><li>Designed for bacteriostatic water and similar liquid samples</li><li>Analysis by HPLC</li><li>Results reported in mg/ml</li><li>Minimum concentration for evaluation: 1 mg/ml</li><li>Minimum sample amount: 1 ml</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Benzyl Alcohol</li><li>Testing method: HPLC</li><li>Minimum concentration of target compound for evaluation: 1 mg/ml</li><li>Result format: mg/ml</li><li>Minimum sample amount: 1 ml</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for benzyl alcohol in liquid samples. It does not automatically screen the sample for other preservatives, active compounds, contaminants, or undeclared substances.</li><li>Samples containing less than 1 mg/ml benzyl alcohol may not be reliably evaluated within the standard scope of the analysis.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a> (TAMC and TYMC)</li></ul>

BAM-15 analysis

Targeted HPLC analysis of BAM-15 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The BAM-15 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of BAM-15 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). BAM-15 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About BAM-15</h4>BAM-15 is a small-molecule research compound that acts as a mitochondrial uncoupler. It increases proton transport across the inner mitochondrial membrane, thereby uncoupling nutrient oxidation from ATP production and altering cellular energy metabolism.BAM-15 has been investigated mainly in preclinical research focused on mitochondrial function, energy expenditure, glucose and lipid metabolism, and related metabolic processes<h4>Key Features</h4><ul><li>Targeted identification and quantification of BAM-15</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: BAM-15</li><li>Other name: BAM15</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>BAM-15 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for BAM-15. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances unless an additional screening service is ordered.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products focused on Laboratory analysis - page 8

Related content

Oligonucleotide and mRNA Analysis Resource Roundup

Conversion to mzML Format for NIST26 Chromatogram Processing

Surpassing the Limits of Traditional Microplastic Analysis Methods with Thermal Desorption and Pyrolysis GCxGC-TOFMS